Pharma Pulse 11/19/24: Is Any Data Better Than No Data? Exploring Emerging Vitiligo Therapies & more

Are Any Data in Clinical Trials Better than No Data At All?
The answer comes down to context of use—and knowing the motives for "missingness."

Exploring Emerging Therapies in Vitiligo
The panelist discusses how emerging targeted therapies like Janus kinase inhibitors and combination treatment approaches are transforming vitiligo management, with treatment selection guided by disease patterns, progression rates and individual patient response, while acknowledging the need for systematic assessment and alternative strategies for treatment-resistant cases.

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
Makers of Ozempic, Zepbound fight to stop compounded copies of their drugs; unclear whether pharmaceutical companies can increase production enough.


Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions
Hims & Hers Health, Inc. announced Deb Autor, former deputy commissioner at the FDA, will join the company’s board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confidence that the solutions they have access to are safe, high-quality, and personalized for their needs.

Biohaven on LinkedIn
Our Chief Medical Officer, Irfan Qureshi, M.D., was recently featured in an article from Pharmaceutical Executive discussing his career, Biohaven’s pipeline and company culture. Check it out:
#BeBiohaven

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs